Australia · Delayed Price · Currency is AUD Australian Clinical Labs Statistics
Total Valuation
ASX:ACL has a market cap or net worth of AUD 523.12 million. The enterprise value is 792.00 million.
| Market Cap | 523.12M |
| Enterprise Value | 792.00M |
Important Dates
The next estimated earnings date is Wednesday, February 25, 2026.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | Sep 1, 2025 |
Share Statistics
ASX:ACL has 194.47 million shares outstanding. The number of shares has decreased by -4.64% in one year.
| Current Share Class | 194.47M |
| Shares Outstanding | 194.47M |
| Shares Change (YoY) | -4.64% |
| Shares Change (QoQ) | -11.47% |
| Owned by Insiders (%) | 2.54% |
| Owned by Institutions (%) | 93.24% |
| Float | 176.74M |
Valuation Ratios
The trailing PE ratio is 15.78 and the forward PE ratio is 14.29. ASX:ACL's PEG ratio is 0.87.
| PE Ratio | 15.78 |
| Forward PE | 14.29 |
| PS Ratio | 0.71 |
| PB Ratio | 3.04 |
| P/TBV Ratio | 85.13 |
| P/FCF Ratio | 3.00 |
| P/OCF Ratio | 2.86 |
| PEG Ratio | 0.87 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.88, with an EV/FCF ratio of 4.54.
| EV / Earnings | 24.42 |
| EV / Sales | 1.07 |
| EV / EBITDA | 3.88 |
| EV / EBIT | 11.65 |
| EV / FCF | 4.54 |
Financial Position
The company has a current ratio of 0.55, with a Debt / Equity ratio of 1.69.
| Current Ratio | 0.55 |
| Quick Ratio | 0.44 |
| Debt / Equity | 1.69 |
| Debt / EBITDA | 1.42 |
| Debt / FCF | 1.67 |
| Interest Coverage | 4.66 |
Financial Efficiency
Return on equity (ROE) is 18.77% and return on invested capital (ROIC) is 8.96%.
| Return on Equity (ROE) | 18.77% |
| Return on Assets (ROA) | 7.28% |
| Return on Invested Capital (ROIC) | 8.96% |
| Return on Capital Employed (ROCE) | 18.97% |
| Revenue Per Employee | 157,717 |
| Profits Per Employee | 6,900 |
| Employee Count | 4,700 |
| Asset Turnover | 1.27 |
| Inventory Turnover | 28.99 |
Taxes
In the past 12 months, ASX:ACL has paid 15.36 million in taxes.
| Income Tax | 15.36M |
| Effective Tax Rate | 31.88% |
Stock Price Statistics
The stock price has decreased by -25.07% in the last 52 weeks. The beta is 1.05, so ASX:ACL's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -25.07% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 2.86 |
| Relative Strength Index (RSI) | 58.36 |
| Average Volume (20 Days) | 733,310 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:ACL had revenue of AUD 741.27 million and earned 32.43 million in profits. Earnings per share was 0.17.
| Revenue | 741.27M |
| Gross Profit | 270.86M |
| Operating Income | 68.00M |
| Pretax Income | 48.18M |
| Net Income | 32.43M |
| EBITDA | 81.36M |
| EBIT | 68.00M |
| Earnings Per Share (EPS) | 0.17 |
Balance Sheet
The company has 22.12 million in cash and 290.38 million in debt, giving a net cash position of -268.26 million or -1.38 per share.
| Cash & Cash Equivalents | 22.12M |
| Total Debt | 290.38M |
| Net Cash | -268.26M |
| Net Cash Per Share | -1.38 |
| Equity (Book Value) | 171.98M |
| Book Value Per Share | 0.88 |
| Working Capital | -96.34M |
Cash Flow
In the last 12 months, operating cash flow was 182.80 million and capital expenditures -8.41 million, giving a free cash flow of 174.39 million.
| Operating Cash Flow | 182.80M |
| Capital Expenditures | -8.41M |
| Free Cash Flow | 174.39M |
| FCF Per Share | 0.90 |
Margins
Gross margin is 36.54%, with operating and profit margins of 9.17% and 4.37%.
| Gross Margin | 36.54% |
| Operating Margin | 9.17% |
| Pretax Margin | 6.50% |
| Profit Margin | 4.37% |
| EBITDA Margin | 10.98% |
| EBIT Margin | 9.17% |
| FCF Margin | 23.53% |
Dividends & Yields
This stock pays an annual dividend of 0.13, which amounts to a dividend yield of 4.63%.
| Dividend Per Share | 0.13 |
| Dividend Yield | 4.63% |
| Dividend Growth (YoY) | 4.17% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 76.92% |
| Buyback Yield | 4.64% |
| Shareholder Yield | 9.37% |
| Earnings Yield | 6.20% |
| FCF Yield | 33.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ASX:ACL has an Altman Z-Score of 2.5 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.5 |
| Piotroski F-Score | 7 |